2,548 Shares in Natera, Inc. (NASDAQ:NTRA) Bought by Syon Capital LLC

Syon Capital LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 2,548 shares of the medical research company's stock, valued at approximately $403,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Principal Securities Inc. increased its position in Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after buying an additional 59 shares during the period. Gladstone Institutional Advisory LLC grew its position in shares of Natera by 1.7% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company's stock worth $574,000 after acquiring an additional 61 shares during the last quarter. Silver Oak Securities Incorporated increased its holdings in shares of Natera by 3.1% in the 4th quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company's stock worth $470,000 after acquiring an additional 89 shares during the period. Blue Trust Inc. increased its holdings in shares of Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after acquiring an additional 97 shares during the period. Finally, Hanseatic Management Services Inc. lifted its position in Natera by 12.0% in the 4th quarter. Hanseatic Management Services Inc. now owns 998 shares of the medical research company's stock valued at $158,000 after purchasing an additional 107 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Sanford C. Bernstein raised their price target on shares of Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a research note on Friday, January 10th. The Goldman Sachs Group raised their target price on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Barclays reduced their price target on Natera from $200.00 to $160.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. Piper Sandler raised their price target on Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Tuesday, March 4th. Finally, StockNews.com upgraded shares of Natera from a "sell" rating to a "hold" rating in a research note on Wednesday, March 19th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and an average target price of $175.76.

Insider Buying and Selling

In other Natera news, insider John Fesko sold 343 shares of Natera stock in a transaction on Monday, April 21st. The shares were sold at an average price of $145.55, for a total transaction of $49,923.65. Following the completion of the sale, the insider now owns 156,946 shares of the company's stock, valued at $22,843,490.30. This trade represents a 0.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Michael Burkes Brophy sold 1,442 shares of the company's stock in a transaction on Monday, January 27th. The stock was sold at an average price of $161.87, for a total transaction of $233,416.54. Following the completion of the transaction, the chief financial officer now directly owns 108,032 shares in the company, valued at $17,487,139.84. This trade represents a 1.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 198,743 shares of company stock valued at $30,558,447. Corporate insiders own 7.60% of the company's stock.

Natera Trading Down 0.4 %

Shares of NTRA stock traded down $0.69 during trading hours on Friday, reaching $153.79. 806,949 shares of the stock traded hands, compared to its average volume of 1,383,185. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $20.79 billion, a PE ratio of -87.38 and a beta of 1.80. Natera, Inc. has a 1-year low of $90.88 and a 1-year high of $183.00. The business has a fifty day moving average price of $147.95 and a 200 day moving average price of $153.71.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.01. The company had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, equities research analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.